<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS & PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
...read full article on Business Wire
